CORO1A links inflammatory chondrocyte subpopulations to immune microenvironment alterations in osteoarthritis: an integrative multi-omics and single-cell study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CORO1A associates inflammatory chondrocyte subsets with changes in the immune microenvironment in osteoarthritis: a comprehensive multi-omics and single-cell analysis

  • By

  • Qiujian Liang

  • Chao Ning

  • Shiyao Gao

  • Dongxin Liu

  • Jinmin Zhao

  • Linke Huang

  • Jun Hou

  • Zhen Tan

  • June 11, 2026

Share

  • 1

    CORO1A is significantly expressed in osteoarthritic cartilage, particularly in inflammatory and proliferative chondrocyte subpopulations.

  • 2

    Increased CORO1A expression correlates with immune cell infiltration, including M2 macrophages and natural killer cells, in osteoarthritis.

  • 3

    CORO1A upregulation activates IL-6/JAK-STAT3 and TNF-α/NF-κB signaling pathways, contributing to cartilage degradation in osteoarthritis.

  • 4

    Experimental data show that suppressing CORO1A reduces MMP13 expression and chondrocyte migration, indicating its functional role in inflammation.

  • 5

    The study highlights CORO1A as a potential therapeutic target for osteoarthritis by linking immune remodeling to chondrocyte populations.

Original Source(s)

CORO1A links inflammatory chondrocyte subpopulations to immune microenvironment alterations in osteoarthritis: an integrative multi-omics and single-cell study

  • by Qiujian Liang, Chao Ning, Shiyao Gao, Dongxin Liu, Jinmin Zhao, Linke Huang, Jun Hou, Zhen Tan

  • June 11, 2026

Related Content

Integrated post-GWAS, single-cell, and functional analyses prioritize TCTN2 at an osteoarthritis locus associated with innate immunity-related cartilage remodeling

Radon balneotherapy in rheumatologic diseases: potential mechanisms and implications for cardiovascular autonomic control and inflammation

CAA Use Tied to Higher Arthroplasty Risk

In a UK cohort, patients with osteoarthritis who initiated centrally acting analgesics had a higher hazard of knee or hip replacement than those who initiated SSRIs, though residual confounding by pain severity remains a key limitation.